eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

The series B round for eTheRNA will fund the Belgian company’s core immuno-oncology pipeline as well as its different mRNA approach to combat the threat of coronaviruses.

eTheRNA immunotherapies N.V. said Tuesday it raised €34 million ($38.2 million) in a series B round. The deal included new investors Grand Decade, a subsidiary of China Grand Pharmaceutical and Healthcare Holdings Ltd. (HKEX:512); Yijing Capital; BNP Paribas Fortis Private Equity; and Novalis LifeSciences LLC. Existing investors Boehringer Ingelheim Venture Fund, Fund+, LSP, PMV and Omega Funds also participated...